BIVM (basic, immunoglobulin-like variable motif-containing) gene, transcriptional products, and uses thereof

An isolated or recombinant polynucleotide:

• a) comprising SEQ ID NO:
• 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 28;
• b) comprising a polynucleotide sequence complementary to a polynucleotide sequence comprising 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 28;
• c) comprising a fragment of a polynucleotide selected from the group consisting of SEQ ID NO:
• 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 28;
• d) comprising a fragment of SEQ ID NO:
• 1 consisting of a) nucleotides 1446 to 1697, orb) nucleotides 1146 to 1698;
• e) comprising a probe or primer comprising 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, or 255 consecutive nucleotides of:
• i) SEQ ID NO:
• 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 28;
• or ii) 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, or 255 consecutive nucleotides of a polynucleotide sequence complementary to SEQ ID NO:
• 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 28;
• f) a polynucleotide sequence having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent identity with a full length polynucleotide sequence selected from the group consisting of SEQ ID NO:
• 1, 3, 4, 6, 7, 10, 12, 14, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 28;
• g) comprising a polynucleotide encoding a polypeptide selected from the group consisting of SEQ ID NO:
• 2, 5, 8, 9, 11, 13, 15, 17, and 27;
• h) comprising a vector comprising a polynucleotide sequence as set forth in 1a), 1b), 1c), 1d), 1e), 1f), or 1g);
• i) comprising a promoter operably linked to a polynucleotide sequence as set for the in comprising a vector comprising a polynucleotide sequence as set forth in 1a), 1b), 1c), 1d), 1e), 1f), or 1g);
• j) a polynucleotide as set forth in 1a), 1b), 1c), 1d), 1e), 1f), or 1g) further comprising a detectable label;
• or
• k) a polynucleotide as set forth in 1a), 1b), 1c), 1d), 1e), 1f), or 1g) further comprising a heterologous polynucleotide sequence encoding a heterologous polypeptide sequence.